WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007003056) CATHEPSIN CYSTEINE PROTEASE INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/003056    International Application No.:    PCT/CA2006/001104
Publication Date: 11.01.2007 International Filing Date: 05.07.2006
IPC:
C07D 231/12 (2006.01), A61K 31/415 (2006.01)
Applicants: MERCK FROSST CANADA LTD. [CA/CA]; 16711 Trans-canada Highway, Kirkland, Québec H9H 3L1 (CA) (For All Designated States Except US).
BLACK, Cameron [CA/CA]; (CA) (For US Only).
CRANE, Sheldon [CA/CA]; (CA) (For US Only).
OBALLA, Renata [CA/CA]; (CA) (For US Only).
ROBICHAUD, Joel [CA/CA]; (CA) (For US Only)
Inventors: BLACK, Cameron; (CA).
CRANE, Sheldon; (CA).
OBALLA, Renata; (CA).
ROBICHAUD, Joel; (CA)
Agent: OGILVY RENAULT LLP/S.E.N.C.R.L., s.r.l.; Suite 1600, 1981 Mcgill College Avenue, Montréal, Québec H3A 2Y3 (CA)
Priority Data:
60/696,970 06.07.2005 US
Title (EN) CATHEPSIN CYSTEINE PROTEASE INHIBITORS
(FR) INHIBITEURS DE CYSTÉINE PROTÉASES DE TYPE CATHEPSINE
Abstract: front page image
(EN)This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of R1 , R2 and R3 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsms K, L, S and B These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis, osteoarthritis and rheumatoid arthritis.
(FR)La présente invention concerne une nouvelle classe de composés de formule ci-dessous, où les valeurs de R1, R2 et R3 sont telles qu'indiquées dans la description, lesdits composés étant des inhibiteurs de cystéine protéase, incluant sans y être limité des inhibiteurs des cathepsines K, L, S et B. Ces composés peuvent être employés dans le traitement de maladies pouvant requérir l'inhibition de la résorption des os, telles que l'ostéoporose, l'ostéoarthrite et la polyarthrite rhumatoïde.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)